Female Facial hair
Buy Vaniqa Cream Online
Studies into the effectiveness of Vaniqa, have shown that 70% of women improve with the treatment. 3 out of 10 show significant improvement after just 24 weeks of use.
Once you have completed the online doctor consultation, our doctor will review your assessment and prescribe you Vaniqa if appropriate. Our pharmacy will then dispense your prescription.
The cost of Vaniqa is amongst the most competitive online.
Excessive Female Facial Hair, defined as hair which grows very dark and thickly on the face, affects many women across the UK. Vaniqa cream, can be a simple and long-lasting solution to the problem of excessive and thick, unwanted facial hair. It generally takes between eight weeks and four months to have noticeable effects, and is applied twice a day to the affected areas.
Female Facial Hair (Hirsutism) In women who suffer from excess female facial hair, the hair is usually thick and dark, rather than fine and fair.
Excess hair can appear on the:
The mostly skin related adverse reactions reported were primarily mild in intensity and resolved without discontinuation of Vaniqa or initiation of medical treatment. The most frequently reported adverse reaction was acne, which was generally mild. In the vehicle controlled trials (n=596), acne was observed in 41% of patients at baseline; 7% of patients treated with Vaniqa and 8% treated with vehicle experienced a worsening of their condition. Of those with no acne at baseline, similar percentages (14%) reported acne following treatment with Vaniqa or vehicle.
The following listing notes the frequency of adverse skin reactions seen in clinical trials, according to MedDRA convention. MedDRA conventions for frequency are very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data) including isolated reports. Note that over 1350 patients were treated with Vaniqa in these trials for 6 months to one year, while only slightly more than 200 patients were treated with vehicle for 6 months. Most events were reported at similar rates between Vaniqa and vehicle. The skin effects of burning, stinging, tingling, rash and erythema were reported at higher levels in Vaniqa treated patients compared to vehicle, as indicated by the asterisk (*).
Frequency of adverse skin reactions seen in Vaniqa clinical trials, (according to MedDRA frequency convention).
Skin and subcutaneous tissue disorders
(≥1/100 to <1/10)
Pseudofolliculitis barbae, alopecia, stinging skin*, burning skin*, dry skin, pruritus, erythema*, tingling skin*, irritated skin, rash*, folliculitis
(≥1/1,000 to <1/100)
Ingrown hair, oedema face, dermatitis, oedema mouth, papular rash, bleeding skin, herpes simplex, eczema, cheilitis, furunculosis, contact dermatitis, abnormal hair texture and abnormal hair growth, hypopigmentation, flushing skin, lip numbness, skin soreness
(≥1/10,000 to <1/1,000)
Rosacea, seborrheic dermatitis, skin neoplasm, maculopapular rash, skin cysts, vesiculobullous rash, skin disorder, hirsutism, skin tightness
Patient Information Leaflet
Always read the patient information leaflet before commencing treatment. Patient information can be found here.
HOW IT WORKS
Start consultation and pay £5
Doctor approves your request.
You pay for your product.
Your product is posted
Royal Mail Tracked